Advanced renal cell carcinoma (ARCC) is a type of kidney cancer that originates in the proximal convoluted tubule. Recent studies suggest that VEGFR inhibitors, like tivozanib, can be a possible treatment of ARCC. However, sorafenib, another kinase inhibitor drug, is also used in the treatment of renal cell carcinoma. This study aims to compare the safety and efficacy of tivozanib and sorafenib in patients with ARCC.

This is a randomized, controlled, open-label study conducted at 120 academic hospitals in 12 countries. The study included a total of 350 patients aged 18 years and older with histologically or cytologically confirmed metastatic renal cell carcinoma. The participants were assigned in a 1:1 ratio to receive either tivozanib 1.5 mg (n=175) or sorafenib 400 mg (n=175). The primary outcome of the study was progression-free survival.

At a follow-up of 19.0 months, median progression-free survival was significantly longer in the tivozanib group (5.6 months) than in the sorafenib group (3.9 months). Treatment-related adverse events occurred in 20% of the patients in the tivozanib group and 14% of the patients in the sorafenib group.

The research concluded that tivozanib as a therapy for advanced renal cell carcinoma resulted in improved progression-free survival than sorafenib.